Novel insights into glucocorticoid-mediated diabetogenic effects: Towards expansion of therapeutic options?

European Journal of Clinical Investigation

Volumn 39, Issue 2, 2009, Pages 81-93

  Van Raalte, D H ^a   Ouwens, D M ^b   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

11 hydroxysteroid dehydrogenases; Beta cell function; Dissociating glucocorticoid receptor agonists; Glucocorticoids; Insulin resistance

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; ADIPOCYTOKINE; AL 438; ANTIDIABETIC AGENT; BI 115; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR AGONIST DERIVATIVE; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; INSULIN; OXIDOREDUCTASE INHIBITOR; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; CELL FUNCTION; CUSHING SYNDROME; DIABETOGENESIS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; FAT CONTENT; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SECRETION; REVIEW; SKELETAL MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; BODY FAT DISTRIBUTION; CORTISONE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; MICE; MUSCLE, SKELETAL; RATS; RECEPTORS, GLUCOCORTICOID;

EID: 58649095526     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02067.x     Document Type: Review

References (139)

1. Mcmahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988 4 : 17 30.
2. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002 96 : 23 43.
3. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003 149 : 561 7.
4. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003 149 : 543 8.
5. Taskinen MR, Nikkila EA, Pelkonen R, Sane T. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 1983 57 : 619 26.
6. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000 21 : 697 738.
7. Khaleeli AA, Edwards RH, Gohil K, Mcphail G, Rennie MJ, Round J et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 1983 18 : 155 66.
8. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997 99 : 414 23.
9. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 1999 42 : 936 43.
10. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366 : 1059 62.
11. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI. Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab 2001 86 : 1149 53.
12. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001 142 : 1371 6.
13. Witchel SF, Defranco DB. Mechanisms of disease: regulation of glucocorticoid and receptor levels-impact on the metabolic syndrome. Nat Clin Pract Endocrinol Metab 2006 2 : 621 31.
14. Seckl JR. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr Opin Pharmacol 2004 4 : 597 602.
15. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005 54 : 1023 31.
16. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev 2005 26 : 452 64.
17. Schacke H, Rehwinkel H, Asadullah K, Cato AC. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol 2006 15 : 565 73.
18. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007 157 : 545 59.
19. Defronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 1981 30 : 1000 7.
20. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997 40 : 1439 48.
21. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982 54 : 131 8.
22. Krebs M, Krssak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 2002 51 : 599 605.
23. Elks ML. Fat oxidation and diabetes of obesity: the Randle hypothesis revisited. Med Hypotheses 1990 33 : 257 60.
24. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003 27 (Suppl. 3 S6 11.
25. Ewart HS, Somwar R, Klip A. Dexamethasone stimulates the expression of GLUT1 and GLUT4 proteins via different signalling pathways in L6 skeletal muscle cells. FEBS Lett 1998 421 : 120 4.
26. Long W, Barrett EJ, Wei L, Liu Z. Adrenalectomy enhances the insulin sensitivity of muscle protein synthesis. Am J Physiol Endocrinol Metab 2003 284 : E102 9.
27. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005 48 : 2119 30.
28. Saad MJ, Folli F, Kahn JA, Kahn CR. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 1993 92 : 2065 72.
29. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998 47 : 3 6.
30. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983 72 : 1814 20.
31. Henriksen JE, Alford F, Vaag A, Handberg A, Beck-Nielsen H. Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 1999 48 : 1128 35.
32. Ekstrand A, Schalin-Jantti C, Lofman M, Parkkonen M, Widen E, Franssila-Kallunki A et al. The effect of (steroid) immunosuppression on skeletal muscle glycogen metabolism in patients after kidney transplantation. Transplantation 1996 61 : 889 93.
33. Lofberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest 2002 32 : 345 53.
34. Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. J Clin Invest 1998 101 : 1519 29.
35. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008 197 : 1 10.
36. Dinneen S, Alzaid A, Miles J, Rizza R. Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am J Physiol 1995 268 : E595 603.
37. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002 32 (Suppl. 3 14 23.
38. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963 1 : 785 9.
39. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2003 285 : E685 92.
40. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999 96 : 513 23.
41. Nielsen MF, Caumo A, Chandramouli V, Schumann WC, Cobelli C, Landau BR et al. Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab 2004 286 : E102 E110.
42. Rooney DP, Neely RD, Cullen C, Ennis CN, Sheridan B, Atkinson AB et al. The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab 1993 77 : 1180 3.
43. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007 275 : 43 61.
44. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 1992 89 : 6035 9.
45. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR. Hormonal control of substrate cycling in humans. J Clin Invest 1988 81 : 1545 55.
46. Schneiter P, Tappy L. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol 1998 275 : E806 13.
47. Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 1980 50 : 495 501.
48. Wajngot A, Khan A, Giacca A, Vranic M, Efendic S. Dexamethasone increases glucose cycling, but not glucose production, in healthy subjects. Am J Physiol 1990 259 : E626 32.
49. Jin JY, Dubois DC, Almon RR, Jusko WJ. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. J Pharmacol Exp Ther 2004 309 : 328 39.
50. Sasaki K, Cripe TP, Koch SR, Andreone TL, Petersen DD, Beale EG et al. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. J Biol Chem 1984 259 : 15242 51.
51. Vander Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, Vander Kooi CW et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol 2005 19 : 3001 22.
52. Zimmerman T, Horber F, Rodriguez N, Schwenk WF, Haymond MW. Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Diabetes 1989 38 : 1238 44.
53. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 1984 64 : 170 259.
54. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002 51 : 1066 75.
55. Chevalier S, Burgess SC, Malloy CR, Gougeon R, Marliss EB, Morais JA. The greater contribution of gluconeogenesis to glucose production in obesity is related to increased whole-body protein catabolism. Diabetes 2006 55 : 675 81.
56. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 2000 19 : 29 34.
57. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 2003 9 : 1069 75.
58. Bernal-Mizrachi C, Xiaozhong L, Yin L, Knutsen RH, Howard MJ, Arends JJ et al. An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension. Cell Metab 2007 5 : 91 102.
59. Van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR) -alpha: a pharmacological target with a promising future. Pharm Res 2004 21 : 1531 8.
60. Opherk C, Tronche F, Kellendonk C, Kohlmuller D, Schulze A, Schmid W et al. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol Endocrinol 2004 18 : 1346 53.
61. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007 132 : 2191 207.
62. Giudetti AM, Gnoni GV. Short-term effect of dexamethasone on fatty acid and cholesterol synthesis in isolated rat hepatocytes. Biochem Mol Biol Int 1998 44 : 515 21.
63. Cole TG, Wilcox HG, Heimberg M. Effects of adrenalectomy and dexamethasone on hepatic lipid metabolism. J Lipid Res 1982 23 : 81 91.
64. Shteyer E, Liao Y, Muglia LJ, Hruz PW, Rudnick DA. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology 2004 40 : 1322 32.
65. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003 149 : 543 8.
66. Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg) 1977 24 : 415 8.
67. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, Hakkinen AM, Andrew R, Wake DJ et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 2003 88 : 4924 31.
68. Ettinger WH Jr., Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988 37 : 1055 8.
69. Taskinen MR, Kuusi T, Yki-Jarvinen H, Nikkila EA. Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. J Clin Endocrinol Metab 1988 67 : 291 9.
70. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008 36 : 146 64.
71. Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 1991 230 : 195 201.
72. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005 1 : 291 9.
73. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004 89 : 2548 56.
74. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003 46 : 1594 603.
75. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 2004 89 : 2989 97.
76. Turnbow MA, Keller SR, Rice KM, Garner CW. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem 1994 269 : 2516 20.
77. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000 49 : 1700 8.
78. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003 46 : 1594 603.
79. Patel JV, Cummings DE, Girod JP, Mascarenhas AV, Hughes EA, Gupta M et al. Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment. J Negat Results Biomed 2006 5 : 14.
80. Lewandowski KC, Szosland K, Lewinski A. Short-term dexamethasone administration does not alter serum adiponectin or resistin concentrations in overweight and obese subjects despite an increase in insulin resistance. Clin Endocrinol (Oxf) 2006 65 : 551 2.
81. Libe R, Morpurgo PS, Cappiello V, Maffini A, Bondioni S, Locatelli M et al. Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clin Endocrinol (Oxf) 2005 62 : 30 6.
82. Udden J, Bjorntorp P, Arner P, Barkeling B, Meurling L, Rossner S. Effects of glucocorticoids on leptin levels and eating behaviour in women. J Intern Med 2003 253 : 225 31.
83. Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res 1994 35 : 1535 41.
84. Divertie GD, Jensen MD, Miles JM. Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 1991 40 : 1228 32.
85. Samra JS, Clark ML, Humphreys SM, Macdonald IA, Bannister PA, Frayn KN. Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab 1998 83 : 626 31.
86. Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE et al. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab 2002 283 : E172 7.
87. Ottosson M, Vikman-Adolfsson K, Enerback S, Olivecrona G, Bjorntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994 79 : 820 5.
88. Arner P, Lithell H, Wahrenberg H, Bronnegard M. Expression of lipoprotein lipase in different human subcutaneous adipose tissue regions. J Lipid Res 1991 32 : 423 9.
89. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004 59 : 359 93.
90. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003 46 : 3 19.
91. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999 104 : 787 94.
92. Barseghian G, Levine R. Effect of corticosterone on insulin and glucagon secretion by the isolated perfused rat pancreas. Endocrinology 1980 106 : 547 52.
93. Billaudel B, Mathias PC, Sutter BC, Malaisse WJ. Inhibition by corticosterone of calcium inflow and insulin release in rat pancreatic islets. J Endocrinol 1984 100 : 227 33.
94. Brunstedt J, Nielsen JH. Direct long-term effect of hydrocortisone on insulin and glucagon release from mouse pancreatic islets in tissue culture. Acta Endocrinol (Copenh) 1981 96 : 498 504.
95. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 1997 272 : 3216 22.
96. Jeong IK, Oh SH, Kim BJ, Chung JH, Min YK, Lee MS et al. The effects of dexamethasone on insulin release and biosynthesis are dependent on the dose and duration of treatment. Diabetes Res Clin Pract 2001 51 : 163 71.
97. Pierluissi J, Navas FO, Ashcroft SJ. Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia 1986 29 : 119 21.
98. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005 54 : 1090 9.
99. Zawalich WS, Tesz GJ, Yamazaki H, Zawalich KC, Philbrick W. Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. Metabolism 2006 55 : 35 42.
100. Nesher R, Anteby E, Yedovizky M, Warwar N, Kaiser N, Cerasi E. Beta-cell protein kinases and the dynamics of the insulin response to glucose. Diabetes 2002 51 (Suppl. 1 S68 73.
101. Ogawa A, Johnson JH, Ohneda M, Mcallister CT, Inman L, Alam T et al. Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest 1992 90 : 497 504.
102. Borboni P, Porzio O, Magnaterra R, Fusco A, Sesti G, Lauro R et al. Quantitative analysis of pancreatic glucokinase gene expression in cultured beta cells by competitive polymerase chain reaction. Mol Cell Endocrinol 1996 117 : 175 81.
103. Khan A, Ostenson CG, Berggren PO, Efendic S. Glucocorticoid increases glucose cycling and inhibits insulin release in pancreatic islets of ob/ob mice. Am J Physiol 1992 263 : E663 6.
104. Hamamdzic D, Duzic E, Sherlock JD, Lanier SM. Regulation of alpha 2-adrenergic receptor expression and signaling in pancreatic beta-cells. Am J Physiol 1995 269 : E162 71.
105. Philippe J, Missotten M. Dexamethasone inhibits insulin biosynthesis by destabilizing insulin messenger ribonucleic acid in hamster insulinoma cells. Endocrinology 1990 127 : 1640 5.
106. Ranta F, Avram D, Berchtold S, Dufer M, Drews G, Lang F et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006 55 : 1380 90.
107. Longano CA, Fletcher HP. Insulin release after acute hydrocortisone treatment in mice. Metabolism 1983 32 : 603 8.
108. Wang ZL, Bennet WM, Wang RM, Ghatei MA, Bloom SR. Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone-treated rats. Endocrinology 1994 135 : 200 6.
109. Mulder H, Ahren B, Stridsberg M, Sundler F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment. Diabetologia 1995 38 : 395 402.
110. Ohneda M, Johnson JH, Inman LR, Unger RH. GLUT-2 function in glucose-unresponsive beta cells of dexamethasone-induced diabetes in rats. J Clin Invest 1993 92 : 1950 6.
111. Grill V, Rundfeldt M. Abnormalities of insulin responses after ambient and previous exposure to glucose in streptozocin-diabetic and dexamethasone-treated rats. Role of hyperglycemia and increased B-cell demands. Diabetes 1986 35 : 44 51.
112. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997 100 : 2094 8.
113. Davani B, Portwood N, Bryzgalova G, Reimer MK, Heiden T, Ostenson CG et al. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 2004 53 (Suppl. 1 S51 9.
114. Kalhan SC, Adam PA. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J Clin Endocrinol Metab 1975 41 : 600 10.
115. Van Raalte DH, Mari A, Bunck MC, Nofrate V, Dokter W, Nassander U et al. Acute and subacute exposure to glucocorticoids differentially impair various aspects of beta-cell function in healthy males (1468-P). 68th Sessions American Diabetes Association. San Francisco, 2008.
116. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 1984 247 : E592 6.
117. Grill V, Pigon J, Hartling SG, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990 39 : 251 8.
118. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 1996 81 : 2621 6.
119. Besse C, Nicod N, Tappy L. Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 2005 13 : 306 11.
120. Cobelli C, Toffolo GM, Dalla MC, Campioni M, Denti P, Caumo A et al. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007 293 : E1 15.
121. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002 283 : E1159 66.
122. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006 54 : 2765 75.
123. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005 365 : 1333 46.
124. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 294 : 2166 70.
125. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004 53 : 931 8.
126. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002 87 : 2701 5.
127. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001 86 : 1418 21.
128. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002 87 : 5630 5.
129. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004 101 : 7088 93.
130. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 2003 88 : 5907 13.
131. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004 47 : 1668 71.
132. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003 34 : 434 9.
133. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007 275 : 109 17.
134. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002 45 : 3813 5.
135. Coppola GM, Kukkola PJ, Stanton JL, Neubert AD, Marcopulos N, Bilci NA et al. Perhydroquinolylbenzamides as novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2005 48 : 6696 712.
136. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003 144 : 4755 62.
137. Julian LD, Wang Z, Bostick T, Caille S, Choi R, Degraffenreid M et al. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J Med Chem 2008 51 : 3953 60.
138. Johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M et al. 2-amino-1,3-thiazol-4 (5H) -ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J Med Chem 2008 51 : 2933 43.
139. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001 414 : 799 806.